Sign In
Buy CAR
$190.46
+4.18 (+2.24%)
At Close: Jun 23, 2026
Avis Wins $650 Million From Hedge Fund That Bet Big on Its Stock
08:37am, Tuesday, 23'rd Jun 2026
Pentwater Capital agrees to pay Avis Budget after it was accused of fueling excess volatility in the car-rental company's stock.
Reasons Why You Should Retain Avis Budget Stock in Your Portfolio
12:41pm, Monday, 15'th Jun 2026
CAR shares jump 28% in a month as pricing improves, fleet utilization hits a 15-year high and earnings are projected to surge in 2026.
Achieved 100% ORR and 83.3% CR rate at dose level 2 following a single infusion in patients with relapsed/refractory B-NHL in an ongoing Phase 1 study Single infusion of LB2501 generated dose-dependen
BRIDGEWATER, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced first clinical proof-of-concept data f
Lyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflection
12:23pm, Saturday, 13'th Jun 2026
Lyell Immunopharma (LYLE) offers asymmetric upside, with ronde-cel showing best-in-class durability and safety in relapsed/refractory LBCL. LYLE trades near cash value, with the market heavily discoun
These 10 Stocks Are Getting Crushed By Short Sellers Right Now
06:17pm, Thursday, 11'th Jun 2026
Short sellers are piling into a wide-ranging group of names, with the latest Benzinga Pro data showing elevated bearish positioning across 10 stocks with short interest ranging from 37% to 87%.
WestGene's established targeted LNP platform combined with Cartesian's mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation Plans
Caribou Biosciences Says CRISPR CAR-T Is Pivotal-Ready, CB-011 Data Nears
06:06am, Tuesday, 09'th Jun 2026
Caribou Biosciences NASDAQ: CRBU Chief Executive Officer Rachel Haurwitz said the company is advancing two CRISPR-enabled, off-the-shelf CAR T cell therapy programs, with its lymphoma candidate vispa-
Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients in stable or progressive disease at lymphodepletion Company reported stron
BRIDGEWATER, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech or the Company), a global leader in cell therapy, today announced that promising prelimin
New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignancies Data highlight potential of DNase I to
Optimization of chelator-to-antibody ratio (CAR) is a key design parameter for next-generation radioconjugates, presenting tunable levers Actinium is utilizing to engineer more effective drug candidat
Why Is Avis Budget (CAR) Down 3.2% Since Last Earnings Report?
12:31pm, Friday, 29'th May 2026
Avis Budget (CAR) reported earnings 30 days ago. What's next for the stock?
A Look at Avis Budget Group Inc (CAR) After 5.9% Gain -- GF Value $130.88 vs Price $174.88
06:58pm, Thursday, 28'th May 2026
On May 28, 2026, Avis Budget Group Inc (CAR) shares rose by 5.9%, bringing the current price to $174.88. This latest movement comes amid a 52-week range that ha
CAR's Strategic Mobility Partnerships Offer Long-Term Opportunities
02:55pm, Thursday, 28'th May 2026
Avis Budget is expanding mobility partnerships and premium services as it positions itself beyond traditional car rentals.
